Altamira Therapeutics Ltd.
Close on Oct 19, 2026
About Altamira Therapeutics
Pharmaceutical Preparations, SIC 2834
Altamira Therapeutics Ltd. is a preclinical-stage biopharmaceutical company focused on developing ribonucleic acid delivery technology. The company develops peptide-based nanoparticle platforms, notably xPhore along with OligoPhore, SemaPhore, and CycloPhore, designed for intracellular nucleotide delivery. Its investigational pipeline includes preclinical drug candidates such as AM-401 and AM-411, alongside legacy programs including the Bentrio nasal spray and the AM-125 vertigo treatment. Altamira primarily serves and engages with commercial partners, pharmaceutical collaborators, and prospective licensees across the biopharmaceutical industry.
The company maintains its principal executive offices in Hamilton, Bermuda. Its research activities and commercial relationships connect entities across North America and Europe, including an intellectual property licensing partnership with an academic institution in Missouri. Additionally, the company holds an interest in an affiliated entity in Switzerland and coordinates preclinical trials through third-party contract research organizations and specialized suppliers located in the United States and European Union member states.
Summary of the business section of Altamira Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Altamira Therapeutics Ltd.
- Headquarters
- Hamilton Hm 11, D0
- Address
- Clarendon House, 2 Church Street 00000
- Phone
- 41 (0) 41 729 71 94
- Website
- altamiratherapeutics.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- D0
- Fiscal year ends
- December 31
- Auditor
- BDO AG, Zurich, Switzerland
Stock & identifiers
- Ticker
- CYTOF
- Exchange
- OTC
- IPO date
- Aug 7, 2014
- Shares outstanding
- 5M, Dec 31, 2024
- Filer category
- Non-accelerated filer
- Stock splits
- 1-for-20 reverse, Apr 10, 2024; 1-for-20 reverse, Dec 13, 2023; 1-for-20 reverse, Nov 30, 2022; 1-for-20 reverse, Oct 25, 2022; 1-for-20 reverse, Aug 15, 2019; 1-for-20 reverse, May 1, 2019; 1-for-10 reverse, Mar 14, 2019; 1-for-10 reverse, Mar 14, 2018
- SEC CIK
- 1601936
- CUSIP
- G0360L134
- ISIN
- USG0360L1340
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Altamira Therapeutics's leadership is listed in its proxy statement (Form DEF 14A).
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 27, 2026 | Deregistration | Termination of SEC registration (Form 15) |
| Jun 17, 2025 | Delisting | Notice of delisting from exchange (Form 25) |
| May 1, 2023 | Late filing | Notification of late filing |
| Apr 11, 2023 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jul 23, 2021 | Name change | Name changed from Auris Medical Holding Ltd. to Altamira Therapeutics Ltd. |
| Mar 14, 2019 | Name change | Name changed from Auris Medical Holding AG to Auris Medical Holding Ltd. |
| Jan 29, 2019 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Mar 13, 2018 | Delisting | Notice of delisting from exchange (Form 25) |
| Mar 13, 2018 | Deregistration | Termination of SEC registration (Form 15) |
| Aug 7, 2014 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 29, 2014 | Listing | Registration of securities on an exchange (Form 8-A) |
| Apr 18, 2014 | Name change | Name changed from Auris Medical AG to Auris Medical Holding AG |